Clinical Trial Update: Efficacy and Safety of Slenyto for Insomnia in Children With ASD [Phase 3]

View source ↗

Summary

Phase 3 trial investigating Slenyto for insomnia in children with autism was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder

Drugs mentioned

• Slenyto (melatonin)

Snippet

Sponsor: Neurim Pharmaceuticals Ltd. | Conditions: Autism Spectrum Disorder | Phase 3 | Status: WITHDRAWN